Genfit to receive EUR 26.5M Iqirvo milestone payment from Ipsen agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2025
0mins
Should l Buy ?
Genfit's Collaboration with Ipsen: Genfit announced that Ipsen's Iqirvo has received pricing and reimbursement approval in Italy for treating Primary Biliary Cholangitis.
Financial Implications: This approval triggers a milestone payment of EUR 26.5 million under their licensing agreement, contingent on similar approvals in three European markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
